NEW YORK, July 11, 2024 /PRNewswire/ -- Olatec Therapeutics, Inc. (Olatec), a leader in the emerging class of specific NLRP3 inhibitors, announced patients with type 2 diabetes mellitus (T2D) and diabetes-related complications (the DAPAN-DIA Study) are being enrolled in a Phase 2 clinical trial in Basel, Switzerland.
Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
Olatec Therapeutics Announces Publication of Preclinical Research on Oral NLRP3-Specific Inhibitor Dapansutrile in Pancreatic Ductal Adenocarcinoma
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced it has completed the lower dose cohort and entered the second, and highest, dose cohort of the DREAM Trial, a Phase 1/2 Investigator-initiated clinical study (NCT04971499). This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma. The study is being led by Principal Investigator (PI), April Salama MD, Head of the Melanoma Program at The Duke Cancer Research Institute and supported by Olatec and Merck & Co., Inc. (Merck). The aim of the DREAM Trial is to address the unmet need in patients with PD-1 refractory advanced melanoma.
Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease Progression
Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Craig T. Basson, MD, PhD has been elected to their Board of Directors.
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company developing cell and gene therapies in virology, oncology, and neurology, today announced it has completed a strategic investment by HMP Partners of New Jersey, a life sciences investment firm managed by medical doctors.
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC (Olatec) is honored to announce inclusion of their clinical heart failure (HF) study in a recent review manuscript authored by leading researchers and clinicians from Oslo University Hospital, Norway, within the high-impact publication, Journal of the American College of Cardiology (JACC): Basic to Translational Review. Titled “Targeting the Inflammasome in Cardiovascular Disease,” this JACC review demonstrates the cardiology community’s growing confidence in the life-prolonging potential of inhibiting NLRP3 activity to preserve heart function. Moreover, Olatec’s growing body of 1) clinical data in HF patients, which quantified cardiovascular improvements in both ejection fraction and exercise time after a 2-week treatment regimen, and 2) preclinical data in models of heart dysfunction, supports dapansutrile’s therapeutic potential to mitigate the progression of HF and treat its symptoms.
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected cancer models. The data in this paper, entitled “Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion”, is published in the Proceedings of the National Academy of Sciences (PNAS). Under leading investigators, including Charles Dinarello MD, Olatec’s CSO, and Mayumi Fujita MD PhD, the data show that blocking NLRP3 with oral dapansutrile resulted in a significant reduction in tumor growth and progression when compared to untreated mice with induced melanoma.